Bleakley Financial Group LLC Makes New $245,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Bleakley Financial Group LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,140 shares of the biopharmaceutical company's stock, valued at approximately $245,000.

A number of other institutional investors also recently bought and sold shares of the business. Choreo LLC purchased a new position in TG Therapeutics during the 4th quarter worth approximately $247,000. Stratos Wealth Advisors LLC purchased a new position in TG Therapeutics during the 4th quarter worth approximately $241,000. Precision Wealth Strategies LLC purchased a new position in TG Therapeutics during the 4th quarter worth approximately $530,000. Symphony Financial Ltd. Co. purchased a new position in TG Therapeutics during the 4th quarter worth approximately $324,000. Finally, Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $75,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $0.02 during trading on Friday, reaching $30.71. The company had a trading volume of 1,179,306 shares, compared to its average volume of 2,274,709. The firm's 50-day simple moving average is $31.15 and its 200 day simple moving average is $27.42. TG Therapeutics, Inc. has a 1-year low of $12.84 and a 1-year high of $36.84. The firm has a market capitalization of $4.78 billion, a PE ratio of -307.07 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TGTX shares. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. Finally, TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.